{
    "clinical_study": {
        "@rank": "144684", 
        "arm_group": [
            {
                "arm_group_label": "Balanced (BAL) anaesthesia", 
                "arm_group_type": "Experimental", 
                "description": "In the BAL group anaesthesia is induced with  midazolam  0.1mg kg-1  and fentanyl  1.5 \u03bcg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40%  and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia."
            }, 
            {
                "arm_group_label": "Totally Intravenous Anesthesia (TIVA-TCI)", 
                "arm_group_type": "Active Comparator", 
                "description": "In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to assess if different anesthetic techniques can affect coagulant factors in\n      patients with prostate cancer undergoing elective  laparoscopic radical prostatectomy (LRP)."
        }, 
        "brief_title": "Prothrombotic Factors and Anaesthesia in Prostate Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostatic Cancer", 
            "Surgery"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The utility of anti-thrombotic prophylaxis in cancer patients undergoing laparoscopic\n      radical prostatectomy (LRP) is still controversial. Moreover, different anaesthetic\n      techniques could modify coagulant factors. Thus, in this study we will be to investigate the\n      variations of pro- and anti-coagulant and fibrinolytic factors in two established types of\n      anaesthesia in patients with prostate cancer undergoing elective LRP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  newly diagnosed cancer of the prostate\n\n          -  histological Gleason score evaluation.\n\n        Exclusion Criteria:\n\n          -  ASA >2\n\n          -  metabolic equivalent  task  < 4\n\n          -  BMI>30\n\n          -  no pre-operative pharmacological thromboprophylaxis and/or anti-coagulant therapy\n\n          -  history of abnormal bleeding, or abnormal  coagulant factors\n\n          -  sepsis within the last 2 weeks\n\n          -  previous new adjuvant treatments (chemo, hormone, and radiotherapy)\n\n          -  non-steroid , anti-inflammatory and statins drugs for at least 2 wks before surgery\n\n          -  venous or arterial thromboembolism within the last 3 months, peripheral venous\n             disease\n\n          -  neurological disease with extremity paresis\n\n          -  chronic liver disease\n\n          -  pre-operative haemoglobin concentration <  9 mg dl-1\n\n          -  prolonged duration of surgery (>3 hrs)\n\n          -  peri-operative blood transfusion\n\n          -  not adequate material for laboratory testing"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998685", 
            "org_study_id": "550"
        }, 
        "intervention": [
            {
                "arm_group_label": "Totally Intravenous Anesthesia (TIVA-TCI)", 
                "intervention_name": "Propofol", 
                "intervention_type": "Drug", 
                "other_name": "Diprivan"
            }, 
            {
                "arm_group_label": "Totally Intravenous Anesthesia (TIVA-TCI)", 
                "intervention_name": "remifentanyl", 
                "intervention_type": "Drug", 
                "other_name": "Ultiva"
            }, 
            {
                "arm_group_label": "Balanced (BAL) anaesthesia", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Balanced (BAL) anaesthesia", 
                "intervention_name": "Fentanyl", 
                "intervention_type": "Drug", 
                "other_name": "Fentanest"
            }, 
            {
                "arm_group_label": "Balanced (BAL) anaesthesia", 
                "intervention_name": "Sevoflurane", 
                "intervention_type": "Drug", 
                "other_name": "Sevorane"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Midazolam", 
                "Fentanyl", 
                "Propofol", 
                "Sevoflurane", 
                "Remifentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostatectomy", 
            "Coagulation Factor", 
            "Balanced Anesthesia", 
            "Intravenous Anesthesia,"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "contact": {
                "email": "forastiere@ifo.it", 
                "last_name": "Ester Forastiere, MD", 
                "phone": "0652662942", 
                "phone_ext": "+ 39"
            }, 
            "contact_backup": {
                "email": "sofra@ifo.it", 
                "last_name": "Maria Sofra, MD", 
                "phone": "0652662942", 
                "phone_ext": "+ 39"
            }, 
            "facility": {
                "address": {
                    "city": "Roma", 
                    "country": "Italy", 
                    "zip": "00144"
                }, 
                "name": "Department of Anaesthesiology, Regina Elena, National Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Maria Sofra, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy", 
        "overall_contact": {
            "email": "sofra@ifo.it", 
            "last_name": "Maria Sofra, MD", 
            "phone": "3288731310", 
            "phone_ext": "+39"
        }, 
        "overall_official": {
            "affiliation": "Department of Anaesthesiology, Regina Elena, National Cancer Institute, Via Elio Chianesi 53, 00144 Roma (Italy); Tel. +39 0652662942, FAX: +39 0652662993; e-mail: forastiere@ifo.it", 
            "last_name": "Ester Forastiere, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of rate of prothrombotic markers and Vascular Endothelial Growth Factor (VEGF) variation", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998685"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Regina Elena Cancer Institute", 
            "investigator_full_name": "Ester Forastiere", 
            "investigator_title": "chief", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Free-desease survivall", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Regina Elena Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regina Elena Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}